HIGHLIGHTS
- who: Andreas Viardot from the Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany have published the research: Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies, in the Journal: (JOURNAL)
- what: The CD19 BiTE therapy blinatumomab has validated the BiTE immuno-oncology platform and raised B-ALL treatment standards, with the first approval of any drug to treat MRD.
- future: Some limitations need to be addressed additional investigation is needed to understand the impact of stepwise dosing on the efficacy of blinatumomab treatment for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.